Format

Send to

Choose Destination
BMC Complement Altern Med. 2017 Sep 18;17(1):465. doi: 10.1186/s12906-017-1971-1.

Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.

Author information

1
Center for Complementary Medicine, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Str. 115B, 79106, Freiburg im Breisgau, Germany. roman.huber@uniklinik-freiburg.de.
2
Helixor Heilmittel GmbH, Rosenfeld, Germany.
3
Clinical Research Dr. Tröger, Freiburg, Germany.

Abstract

BACKGROUND:

Mistletoe extracts have anti-tumor properties and are approved for subcutaneous use in cancer patients. Data on Intravenous application are limited.

METHODS:

An aqueous extract from pine-mistletoe was used to investigate maximum tolerable dose (MTD) and safety of intravenous application. It was infused once weekly for 3 weeks in patients with advanced cancer. Any type of cancer was included; relevant exclusion criteria were concurrent chemo- or radiation therapy. The classical phase I 3 + 3 dose escalation scheme was followed. Predefined dose groups were 200, 400, 700, 1200 and 2000 mg. Maximum planned dose was 2000 mg. With the MTD three more patients should be treated for 9 weeks in order to evaluate intermediate term tolerability. Weekly during the treatment and 1 week later tolerability, clinical status, safety laboratory parameters and adverse events were documented.

RESULTS:

Twenty-one patients (3 in the dose groups 200, 400, 700 and 1200 mg, respectively, 9 in the dose group 2000 mg) were included. MTD was not reached. Because one dose-limiting toxicity (DLT), an allergic reaction, occurred during infusion of 2000 mg, three more patients had to be included in this dose group and tolerated it, as well as the three patients who received 2000 mg for 9 weeks. Occasionally in the dose group 2000 mg mild to moderate fever occurred.

CONCLUSION:

Weekly infusions of 2000 mg of the pine-mistletoe extract were tolerated and can be used in further studies but had a risk for allergic reactions and fever. German Clinical Trials Register (Trial registration number DRKS00005028).

KEYWORDS:

Cancer; Clinical trial; Intravenous; MTD; Side effects; Viscum album

PMID:
28923036
PMCID:
PMC5604151
DOI:
10.1186/s12906-017-1971-1
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center